AJANTPHARM Ajanta Pharmaceuticals Ltd. — Smart-Money Activity, F&O Buildup & Bulk Deals
Sector: Healthcare₹ 3,054.40
-2.45%
Smart Money Verdict synthesis of derivatives, deals, and promoter files
No significant institutional activity detected
Derivative metrics and institutional flows are quiet. No recent bulk deals or insider disclosures have been reported.
Analysis what the data is telling us about AJANTPHARM
Ajanta Pharmaceuticals Ltd. did not have meaningful F&O activity in the last completed session. That doesn't mean the stock is irrelevant — it just means the smart-money signals here come from cash markets and corporate disclosures, covered below.
On the institutional side, MFs are accumulating Ajanta Pharmaceuticals Ltd. — the most recent notable was KOTAK MAHINDRA MUTUAL FUND on the buy side at ₹624 Cr.
Putting it together, the smart-money picture for Ajanta Pharmaceuticals Ltd. is best read as range-bound for now.
F&O Positioning EOD derivatives setup
Buildup Class
—
no futures data
Futures OI
—
EOD details
Option PCR (OI)
—
no EOD options
Max Pain Strike
—
writer loss minimized strike
Quote Details key metrics & weights
Previous Close
₹ 3,131.00
yesterday's EOD close
Index Contribution
—
not a Nifty 50 constituent
Traded Volume
184,691
live shares traded today
Upcoming Earnings
—
no report scheduled
Technical Snapshot from 400 sessions of price history
RSI (14)
60.9
neutral momentum
52-Week High
₹ 3,314.90
-5.5% from high
52-Week Low
₹ 2,329.90
+34.4% above low
200-DMA
₹ 2,743.79
+14.1% · above trend
50-DMA
₹ 2,952.65
+6.0% from 50-DMA
1-Year Return
+21.8%
1M -3.9%
Key Fundamentals headline ratios · Healthcare
P/E (TTM)
36.1
price / earnings
P/B
8.4
price / book
ROE
25.4%
return on equity
Market Cap
₹ 38,160 Cr
total market value
Dividend Yield
1.79%
trailing yield
EPS (TTM)
₹ 84.54
earnings per share
Fundamental ratios sourced from public market data, refreshed periodically; verify against company filings before relying on them.
Institutional Deals last 30 sessions (bulk & block)
| Date | Side | Price | Value (Cr) | Counterparty |
|---|---|---|---|---|
| 2026-06-09 | SELL | ₹ 2,968.00 | 1,023.96 | RAVI AGRAWAL TRUST |
| 2026-06-09 | SELL | ₹ 2,968.00 | 1,023.96 | RAVI AGRAWAL TRUST |
| 2026-06-09 | BUY | ₹ 2,968.00 | 623.96 | KOTAK MAHINDRA MUTUAL FUND MF |
| 2026-06-09 | BUY | ₹ 2,968.00 | 623.96 | KOTAK MAHINDRA MUTUAL FUND MF |
| 2026-06-09 | BUY | ₹ 2,968.00 | 400.00 | ADITYA BIRLA SUN LIFE MUTUAL FUND MF |
Insider & Promoter Filings last 60 days
No insider disclosures filed for this stock in the last 60 days.
Latest News recent coverage from Reuters, Simply Wall St, MT Newswires and others
India Semaglutide Patent Expiry Could Drive 50% Price Drop in Weight-Loss Drugs
Ajanta Pharma Ltd (BOM:532331) Q3 2026 Earnings Call Highlights: Strong Revenue Growth and ...
Inspira Global to buy stake in India's Burger King operator RBA for about $50.5 million
Everstone to sell stake in Restaurant Brands Asia – report
Everstone to sell stake in India's Burger King operator Restaurant Brands Asia, sources say
Ajanta Pharma Ltd (BOM:532331) Q2 2026 Earnings Call Highlights: Strong Revenue Growth Amidst ...